Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARDELYX, INC.ARDX · Entity 4972 | Director | June 16, 2026 | June 18, 2026 |
| NOVAVAX INCNVAX · Entity 4632 | Director | June 18, 2026 | June 23, 2026 |
| Opus Genetics, Inc.IRD · Entity 5892 | Director | April 20, 2026 | April 22, 2026 |
| Sagimet Biosciences Inc.SGMT · Entity 5273 | Director | July 18, 2023 | July 20, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARDELYX, INC.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 439,998 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 26,455 · Balance 439,998 F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.67 · Expires 2036-06-16 | Direct | 39,715 |
Reported balance
After 2026-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-16 · Grant · Acquired 39,715 · Balance 39,715 F2: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. The RSUs were issued pursuant to the Issuer's Non-Employee Director Compensation Program.
F2: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program.
F3: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.
NOVAVAX INC
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,370 |
Reported balance
After 2026-06-20 transaction · row 1
1 source rowRow 1 · 2026-06-20 · Exercise / conversion · Acquired 18,880 · Balance 47,370 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.13 · Expires 2036-06-18 | Direct | 21,270 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 21,270 · Balance 21,270 F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,180 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 14,180 · Balance 14,180 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-20 · Exercise / conversion · Disposed 18,880 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2: One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F3: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F4: One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date
Opus Genetics, Inc.
Report date April 20, 2026 · Filed April 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 343,022 |
Reported balance
After 2026-04-20 transaction · row 1
1 source rowRow 1 · 2026-04-20 · Grant · Acquired 24,367 · Balance 343,022 F1: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.
Sagimet Biosciences Inc.
Report date July 18, 2023 · Filed July 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.05 · Expires 2025-03-09 | Direct | 0 |
Reported balance
After 2023-07-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-18 · Disposition to issuer · Disposed 1,976 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: The shares underlying this option are fully vested and exercisable as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.05 · Expires 2025-03-09 | Direct | 1,976 |
Reported balance
After 2023-07-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-07-18 · Grant · Acquired 1,976 · Balance 1,976 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: The shares underlying this option are fully vested and exercisable as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2029-04-27 | Direct | 0 |
Reported balance
After 2023-07-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-07-18 · Disposition to issuer · Disposed 23,216 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: The shares underlying this option are fully vested and exercisable as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2029-04-27 | Direct | 23,216 |
Reported balance
After 2023-07-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-07-18 · Grant · Acquired 23,216 · Balance 23,216 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: The shares underlying this option are fully vested and exercisable as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2031-01-26 | Direct | 0 |
Reported balance
After 2023-07-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-07-18 · Disposition to issuer · Disposed 23,839 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: The shares underlying this option are fully vested and exercisable as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2031-01-26 | Direct | 23,839 |
Reported balance
After 2023-07-18 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-07-18 · Grant · Acquired 23,839 · Balance 23,839 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: The shares underlying this option are fully vested and exercisable as of the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
F2: The shares underlying this option are fully vested and exercisable as of the date hereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2022 Filed Jul 6, 2022 21:58 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 15,841 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-025286 · form4.xml · nonDerivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,276 F2 · price: The Reporting Person was granted shares of common stock in lieu of cash for board services for the second half of 2022. The number of shares was determined by dividing (A) the aggregate amount of the retainer to be earned for board services for such period, by (B) the average fair market value of a share of common stock for the 30 consecutive trading days ending on and including the last trading day prior to the grant date (rounded down to the nearest whole share). The average fair market value was $2.02 per share, the average of the closing price of the common stock for the 30 consecutive trading days prior to July 1, 2022. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 21:58 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 7,812 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-025286 · form4.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,435 F1 · price: The Reporting Person was granted shares of common stock in lieu of cash for board services for the second quarter of 2022. The number of shares of common stock was determined by dividing (A) the aggregate amount of the retainer paid for board services for such fiscal quarter, by (B) the fair market value of the common stock on the last day of the fiscal quarter (rounded down to the nearest whole share). The fair market value was $1.92 per share, the closing price of the common stock on June 30, 2022. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:22 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001567619-22-013086 · doc1.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-06-15 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:22 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 132,299 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013086 · doc1.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,826 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:01 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001140361-22-023052 · form4.xml · derivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-12 F1 · derivative.exercise_date: Will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 13:12 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 4,629 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-013060 · form4.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,623 F1 · price: The Reporting Person was granted shares of common stock in lieu of cash for board services for the first quarter of 2022. The number of shares of common stock was determined by dividing (A) the aggregate amount of the retainer paid for board services for such fiscal quarter, by (B) the fair market value of the common stock on the last day of the fiscal quarter (rounded down to the nearest whole share). The fair market value was $3.24 per share, the closing price of the common stock on March 31, 2022. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:01 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 4,021 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-000659 · form4.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,994 F1 · price: The Reporting Person was granted common stock in lieu of cash for Q4 2021 Board services. The number of shares of Common Stock having an aggregate Fair Market Value equal to the aggregate amount of the Retainers for such fiscal quarter, determined by dividing (A) the aggregate amount of the Retainers by (B) the Fair Market Value of the Common Stock on last day of the fiscal quarter (rounded down to the nearest whole share). The Fair Market Value was $3.73 per share, the closing price of the Company's stock on December 31, 2021. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:01 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 2,912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-033450 · form4.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,973 F1 · price: The Reporting Person was granted common stock in lieu of cash for Q3 2021 Board services. The number of shares of Common Stock having an aggregate Fair Market Value equal to the aggregate amount of the Retainers for such fiscal quarter, determined by dividing (A) the aggregate amount of the Retainers by (B) the Fair Market Value of the Common Stock on last day of the fiscal quarter (rounded down to the nearest whole share). The Fair Market Value was $5.15 per share, the closing price of the Company's stock on September 30, 2021. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:01 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 2,840 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-023334 · form4.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,061 F1 · price: The Reporting Person was granted common stock in lieu of cash for Q2 2021 Board services. The number of shares of Common Stock having an aggregate Fair Market Value equal to the aggregate amount of the Retainers for such fiscal quarter, determined by dividing (A) the aggregate amount of the Retainers by (B) the Fair Market Value of the Common Stock on last day of the fiscal quarter (rounded down to the nearest whole share). The Fair Market Value was $5.28 per share, the closing price of the Company's stock on June 30, 2021. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:10 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 32,765 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001567619-21-012429 · doc1.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,765 Underlying: Common Stock · 32,765 shares Expires 2031-06-16 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:10 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 9,917 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-012429 · doc1.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,527 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:14 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.74 | $0.00 |
DisclosureSEC source: 0001140361-21-020422 · form4.xml · derivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-07 F1 · derivative.exercise_date: Will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 21:43 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 2,581 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-011670 · form4.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,221 F1 · price: The Reporting Person was granted common stock in lieu of cash for Q1 2021 Board services. The number of shares of Common Stock having an aggregate fair market value equal to the aggregate amount of the Retainers for such fiscal quarter, determined by dividing (A) the aggregate amount of the Retainers by (B) the Fair Market Value of the Common Stock on last day of the fiscal quarter (rounded down to the nearest whole share). The Fair Market Value was $5.81 per share, the closing price of the Company's stock on March 31, 2021. Read SEC document |
| November 19, 2020 Filed Nov 26, 2020 01:12 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | PurchaseSeries B Warrant (right to buy) · Derivative | 3,148 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001140361-20-026657 · form4.xml · derivative · entry 3 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,148 Underlying: Common Stock · 3,148 shares Expires 2022-01-28 F2 · shares: Subject to adjustment based on certain price reset provisions. F1 · price: The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $100,000. Read SEC document |
| November 19, 2020 Filed Nov 26, 2020 01:12 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | PurchaseSeries A Warrant (right to buy) · Derivative | 26,789 | Not disclosed Strike: $4.48 | Not disclosed |
DisclosureSEC source: 0001140361-20-026657 · form4.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,789 Underlying: Common Stock · 26,789 shares Expires 2025-11-19 F2 · derivative.exercise_price: Subject to adjustment based on certain price reset provisions. F1 · price: The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $100,000. Read SEC document |
| November 19, 2020 Filed Nov 26, 2020 01:12 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | PurchaseCommon Stock | 17,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-20-026657 · form4.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,640 F1 · price: The Reporting Person purchased shares, Series A Warrants and Series B Warrants as part of a private placement for an aggregate price of $100,000. Read SEC document |
| November 11, 2020 Filed Nov 13, 2020 22:22 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001140361-20-025549 · form4.xml · derivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-11-11 F1 · derivative.exercise_date: 16,666 shares vest each twelve month period ending October 31, 2021 and October 31, 2022 and the balance vest October 31, 2023. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 21:56 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 5,910 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001596771-20-000108 · primary_doc.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,910 F1 · price: The reporting person acquired the shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc., and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:20 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0001567619-20-012029 · doc1.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2030-06-09 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:20 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 9,233 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-012029 · doc1.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,610 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:34 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001567619-19-013483 · doc1.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-06-13 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:34 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 24,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-013483 · doc1.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,377 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 20:19 UTC | Opus Genetics, Inc. RNN · Entity 5892 | GrantStock Option (right to buy) · Derivative | 3,537 | $0.00 Strike: $5.23 | $0.00 |
DisclosureSEC source: 0001140361-19-010676 · form4.xml · derivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,537 Underlying: Common Stock · 3,537 shares Expires 2029-06-06 Read SEC document |
| June 28, 2018 Filed Jun 29, 2018 20:34 UTC | Opus Genetics, Inc. RNN · Entity 5892 | GrantStock Option (right to buy) · Derivative | 39,742 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001140361-18-030728 · form4.xml · derivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,742 Underlying: Common Stock · 39,742 shares Expires 2028-06-28 Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 22:56 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001140361-18-028861 · doc1.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-13 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 22:56 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 16,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-028861 · doc1.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,742 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 23:04 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001140361-17-024617 · doc1.xml · derivative · entry 2 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-07 F2 · shares: The option was issued pursuant to the Issuer's Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The option vests with respect to 1/12th of the shares subject thereto on each monthly anniversary of the grant date, which vesting will accelerate in full on the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 23:04 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 15,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-024617 · doc1.xml · nonDerivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,993 F1 · shares: The shares were issued pursuant to the Issuer's Non-Employee Director Compensation Program. The Reporting Person elected to receive stock in lieu of cash as permitted under the program. Read SEC document |
| April 11, 2017 Filed Apr 12, 2017 21:25 UTC | Opus Genetics, Inc. RNN · Entity 5892 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001140361-17-015709 · form4.xml · derivative · entry 1 Rodgers Richard J · CIK 0001313397 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2027-04-11 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.